- Home
- ANNX vs DDD Comparison
ANNX vs DDD Comparison
Compare ANNX & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- DDD
- Stock Information
- Founded
- ANNX 2011
- DDD 1986
- Country
- ANNX United States
- DDD United States
- Employees
- ANNX N/A
- DDD N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- DDD Computer peripheral equipment
- Sector
- ANNX Health Care
- DDD Technology
- Exchange
- ANNX Nasdaq
- DDD Nasdaq
- Market Cap
- ANNX 334.1M
- DDD 360.4M
- IPO Year
- ANNX 2020
- DDD N/A
- Fundamental
- Price
- ANNX $3.20
- DDD $3.13
- Analyst Decision
- ANNX Strong Buy
- DDD Buy
- Analyst Count
- ANNX 4
- DDD 2
- Target Price
- ANNX $13.00
- DDD $5.00
- AVG Volume (30 Days)
- ANNX 2.0M
- DDD 4.7M
- Earning Date
- ANNX 11-13-2025
- DDD 11-25-2025
- Dividend Yield
- ANNX N/A
- DDD N/A
- EPS Growth
- ANNX N/A
- DDD N/A
- EPS
- ANNX N/A
- DDD N/A
- Revenue
- ANNX N/A
- DDD $413,342,000.00
- Revenue This Year
- ANNX N/A
- DDD N/A
- Revenue Next Year
- ANNX N/A
- DDD $1.78
- P/E Ratio
- ANNX N/A
- DDD N/A
- Revenue Growth
- ANNX N/A
- DDD N/A
- 52 Week Low
- ANNX $1.29
- DDD $1.32
- 52 Week High
- ANNX $7.64
- DDD $5.00
- Technical
- Relative Strength Index (RSI)
- ANNX 58.77
- DDD 53.16
- Support Level
- ANNX $2.89
- DDD $2.94
- Resistance Level
- ANNX $3.36
- DDD $3.80
- Average True Range (ATR)
- ANNX 0.21
- DDD 0.33
- MACD
- ANNX -0.03
- DDD -0.04
- Stochastic Oscillator
- ANNX 67.35
- DDD 28.51
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.